Document is current
Any future updates will be listed below
-
Authors
Garrido-García, Pablo https://orcid.org/0009-0006-8028-7700
Quirós, Irene
Milán-Rois, Paula https://orcid.org/0000-0002-7043-2920
Ortega-Gutiérrez, Silvia https://orcid.org/0000-0002-0257-6754
Martín-Fontecha, Mar https://orcid.org/0000-0002-4848-0109
Campos, Luis A. https://orcid.org/0000-0003-4788-9102
Somoza, Álvaro https://orcid.org/0000-0001-9873-435X
Fernández, Israel https://orcid.org/0000-0002-0186-9774
Rigotti, Thomas https://orcid.org/0000-0002-5115-9543
Tortosa, Mariola https://orcid.org/0000-0002-5107-0549
- License Information
-
More Information
Article History
Received: 6 October 2023
Accepted: 17 January 2025
First Online: 25 February 2025
Competing interests
: The authors declare the following competing financial interests: T.R. and M.T. (Autonomous University of Madrid), and P.M.-R. and A.S. (IMDEA Nanociencia) are listed as inventors on EU patent application number EP24382968, which covers the synthesis of ‘sp3-analogues of axitinib and medical uses thereof’ in the paper. The other authors declare no competing interests.
